Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. https://doi.org/10.1002/cncr.33587.

Article  PubMed  Google Scholar 

Mc Neil V, Lee SW. Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies. Cancers. 2025;17(9):1408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. https://doi.org/10.1097/COC.0000000000000239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik J. Nivolumab plus Relatlimab: first approval. Drugs. 2022;82(8):925–31. https://doi.org/10.1007/s40265-022-01723-1.

Article  CAS  PubMed  Google Scholar 

Corrie K, Hardman JG. Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics. Anaesthesia & Intensive Care Medicine. 2011;12(4):156–9. https://doi.org/10.1016/j.mpaic.2010.12.008.

Article  Google Scholar 

Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, Van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58(7):835–57. https://doi.org/10.1007/s40262-019-00748-2.

Article  PubMed  PubMed Central  Google Scholar 

Grice S, Olsson-Brown A, Naisbitt DJ, Hammond S. Immunological drug–drug interactions affect the efficacy and safety of immune checkpoint inhibitor therapies. Chem Res Toxicol. 2024;37(7):1086–103. https://doi.org/10.1021/acs.chemrestox.4c00067.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stone S, McPherson JP, Kulkarni RP, Young A. The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors. Nat Rev Cancer. Published online 2025:1–22.

Nara K, Taguchi S, Buti S, et al. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. J Immunother Cancer. 2024;12(3):e008806. https://doi.org/10.1136/jitc-2024-008806.

Article  PubMed  PubMed Central  Google Scholar 

Moharasan G, Ho TB. Extraction of temporal information from clinical narratives. J Healthc Inform Res. 2019;3(2):220–44. https://doi.org/10.1007/s41666-019-00049-0.

Article  PubMed  PubMed Central  Google Scholar 

Joshi S, Nadaf H, Jabade M, Pimpalekar S. Oncology in the AI era: Transforming cancer care through intelligent diagnosis and treatment. Artif Intell Oncol Cancer Diagn Treat Med Imaging Pers Med. Published online 2025:595–608.

Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105(4):954–61. https://doi.org/10.1002/cpt.1255.

Article  PubMed  Google Scholar 

Bernatz S, Prudente V, Pai S, et al. Thymic health consequences in adults. Nature. Published online 2026:1–9.

Bernatz S, Prudente V, Pai S, et al. Thymic health and immunotherapy outcomes in patients with cancer. Nature. Published online 2026:1–9.

Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol. 2014;14(6):377–91. https://doi.org/10.1038/nri3667.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101. https://doi.org/10.1186/s13045-023-01499-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825–63. https://doi.org/10.1016/j.ccell.2024.09.010.

Article  CAS  PubMed  Google Scholar 

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. https://doi.org/10.1038/s41572-020-0160-6.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Zhang S, Guo G, Han J, Yu J. Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine. 2022. https://doi.org/10.1016/j.ebiom.2022.104163.

Article  PubMed  PubMed Central  Google Scholar 

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–9. https://doi.org/10.1126/science.aac4255.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7. https://doi.org/10.1126/science.aan3706.

Article  CAS  PubMed  Google Scholar 

Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–8. https://doi.org/10.1126/science.aao3290.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang XZ, Gao P, Song YX, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. OncoImmunology. 2019;8(12):e1665973. https://doi.org/10.1080/2162402X.2019.1665973.

Article  PubMed  PubMed Central  Google Scholar 

Crespin A, Le Bescop C, de Gunzburg J, et al. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front Oncol. 2023;13:1075593. https://doi.org/10.3389/fonc.2023.1075593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gambichler T, Weyer-Fahlbusch SS, Overbeck J, Abu Rached N, Becker JC, Susok L. Impaired overall survival of melanoma patients due to antibiotic use prior to immune checkpoint inhibitor therapy: systematic review and meta-analysis. Cancers Basel. 2025;17(11):1872. https://doi.org/10.3390/cancers17111872.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. OncoImmunology. 2018;7(11):e1507670. https://doi.org/10.1080/2162402X.2018.1507670.

Article  PubMed  PubMed Central  Google Scholar 

Elkrief A, Méndez-Salazar EO, Maillou J, et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis Oncol. 2024;8(1):143. https://doi.org/10.1038/s41698-024-00630-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–6. https://doi.org/10.1126/science.1240537.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jing Y, Chen X, Li K, et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer. 2022;10(1):e003779. https://doi.org/10.1136/jitc-2021-003779.

Article